The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug guides,Pharmacology (nursing)
Link
http://link.springer.com/content/pdf/10.1177/009286150103500416.pdf
Reference13 articles.
1. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharma Stat 1994;4;147–164.
2. O’Quigley J, Chevret S. Methods for dose finding studies in cancer trials: A review and results of a Monte Carlo study. Stat Med 1991;10;1647–1664.
3. O’Quigley J, Pepe M, Fisher M. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 1990;46;33–48.
4. Goodman S, Zahurak M, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14;1149–1161.
5. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med 1995;14;911–922.
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Brief Overview of Adaptive Designs for Phase I Cancer Trials;Cancers;2022-03-18
2. Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols;Contemporary Clinical Trials;2021-09
3. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician;JCO Precision Oncology;2021-01
4. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs;BMC Medicine;2020-11-19
5. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials;Statistics in Medicine;2017-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3